KEGG   DRUG: D09901Help
Entry
D09901                      Drug                                   

Name
Etrolizumab (USAN/INN)
Formula
C6396H9874N1702O2010S42
Exact mass
144029.1017
Mol weight
144117.7642
Sequence
(Heavy chain) EVQLVESGGG LVQPGGSLRL SCAASGFFIT NNYWGWVRQA
PGKGLEWVGY ISYSGSTSYN PSLKSRFTIS RDTSKNTFYL QMNSLRAEDT AVYYCARTGS
SGYFDFWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS
GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC
DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD
GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG
(Disulfide bridge: 22-95; 144-200; 261-321; 367-425, Dimer: 226; 229)
(Light chain) DIQMTQSPSS LSASVGDRVT ITCRASESVD DLLHWYQQKP
GKAPKLLIKY ASQSISGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GNSLPNTFGQ
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: 23-88; 134-194; H220-L214, Dimer)
  Type
Peptide
Activity
Treatment of inflammatory bowel disease
Comment
Monoclonal antibody
Target
integrin alpha4/beta7 [HSA:3676 3695] [KO:K06483 K06590];
integrin alphaE/beta7 [HSA:3682 3695] [KO:K06524 K06590]
  Pathway
hsa04510  Focal adhesion
hsa04512  ECM-receptor interaction
hsa04514  Cell adhesion molecules (CAMs)  
 
Brite
Target-based classification of drugs [BR:br08310]
 Others
  Cell adhesion molecules (CAMs)
   integrin alpha4/beta7
    Etrolizumab
     D09901  Etrolizumab (USAN/INN)
   integrin alphaE/beta7
    Etrolizumab
     D09901  Etrolizumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
1044758-60-2
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system